The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.87

Today's change-0.01 -0.35%
Updated November 22 4:00 PM EST. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.87

Today's change-0.01 -0.35%
Updated November 22 4:00 PM EST. Delayed by at least 15 minutes.

PDL BioPharma Inc down (U.S.)$0.01

PDL BioPharma Inc closed lower Wednesday, dropping (U.S.)$0.01 or 0.35% to (U.S.)$2.87. Over the last five days, shares have gained 3.99% and 35.38% year to date. Shares have underperformed the S&P 500 by 23.17% during the last year.

Key company metrics

  • Open(U.S.) $2.90
  • Previous close(U.S.) $2.88
  • High(U.S.) $2.90
  • Low(U.S.) $2.84
  • Bid / Ask(U.S.) $2.61 / (U.S.) $2.89
  • YTD % change+35.38%
  • Volume789,680
  • Average volume (10-day)1,611,080
  • Average volume (1-month)1,957,248
  • Average volume (3-month)1,915,153
  • 52-week range(U.S.) $1.93 to (U.S.) $3.55
  • Beta0.54
  • Trailing P/E5.70×
  • P/E 1 year forward4.42×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.50
Updated November 22 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.52%

Based on its net profit margin of 24.52%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue631444566
Total other revenue--------
Total revenue631444566
Gross profit571394362
Total cost of revenue6534
Total operating expense32252777
Selling / general / administrative17151513
Research & development1422
Depreciation / amortization6666
Interest expense (income), net operating--------
Unusual expense (income)2-6--57
Other operating expenses, total111-6
Operating income3011919-10
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax2511414-15
Income after tax21607-10
Income tax, total5547-4
Net income21607-10
Total adjustments to net income--------
Net income before extra. items21607-10
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items21607-10
Inc. avail. to common incl. extra. items21607-10
Diluted net income21607-10
Dilution adjustment--------
Diluted weighted average shares152156164164
Diluted EPS excluding extraordinary itemsvalue per share0.140.390.04-0.06
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.150.370.040.16